aortic aneurysm
in review
7 min read
Updated 2026-10-19
aortic aneurysm
Ascending aorta ≥4.0 cm = dilated, ≥4.5 cm = aneurysm. At diagnosis: TTE + CT/MRI of the whole aorta, multigenerational family history, imaging of first-degree relatives, genetics referral if high-risk features. Medical therapy: BP <130/80 with beta-blocker then ARB, smoking cessation, statin if atherosclerotic, avoid heavy isometric exercise and fluoroquinolones. Repair sporadic ascending/root aneurysm at 5.5 cm (5.0 cm at an expert centre), earlier for Marfan, Loeys-Dietz, familial disease or rapid growth; descending at 5.5 cm; AAA at 5.5 cm men / 5.0 cm women. Canada screens men 65–80 once by ultrasound.
mechanism → management
- Laplace: wall tension ∝ radius → risk of dissection/rupture climbs steeply with diameter. Relative dissection risk rises at 4.0–4.4 cm and abruptly at ≥4.5 cm → hence the definitions
- Root/ascending aneurysms are medial degeneration with a congenital or heritable basis (BAV, Marfan, familial); atheroma 8–9%. Descending and abdominal aneurysms are atherosclerotic (atheroma 80–88%) → vascular risk-factor control matters more
- Most type A dissections occur <5.5 cm → thresholds trade one-off operative risk (~1% elective ascending repair) against yearly rupture risk
- Growth (cm/y): sporadic ascending 0.01–0.03, arch 0.25, descending 0.19, AAA 0.26 (faster with smoking). Rapid growth signals unstable wall → intervene regardless of size
- Small (women, Turner) or tall patients: index to BSA (ASI), height, or cross-sectional area/height (≥10 cm²/m)
at diagnosis
- TTE (valve morphology and function, root and ascending diameters) (I) + CT or MRI of the entire aorta (2a). Record height and weight
- Multigenerational family history: TAD, unexplained sudden death, peripheral and intracranial aneurysms (I)
- First-degree relatives: aortic imaging for root/ascending aneurysm or dissection (ACC/AHA I; CCS 2014 strong for genetic TAD); TTE for relatives of BAV patients (CCS 2014 strong)
genetics referral (CCS 2023 — selective)
| Personal history | Family (first- or second-degree) |
|---|---|
| thoracic dissection <50 y, or <60 y without hypertension | thoracic aneurysm/dissection |
| ectopia lentis, dural ectasia, hypertelorism, bifid uvula, craniosynostosis | extra-aortic aneurysm/dissection |
| aneurysm/dissection in other arterial beds, marked arterial tortuosity | sudden death <50 y without alternate cause |
| pneumothorax, braced/operated scoliosis, multiple tendon ruptures, translucent skin, atraumatic bruising, hollow-organ rupture, tissue friability at surgery, much taller than family |
- ACC/AHA tests more broadly: TAD <60 y, family TAD/aneurysm, young sudden death
- Pathogenic variant → cascade genetic testing of relatives, imaging only in carriers (CCS 2014). No variant found but familial pattern → image at-risk relatives anyway (ACC/AHA I)
- The gene sets thresholds (TGFBR1/2, SMAD3, ACTA2, vEDS dissect small); VUS do not guide care
surveillance
| Disorder (CCS 2023) | TTE | CT or MRI |
|---|---|---|
| Loeys-Dietz, ACTA2 | yearly | yearly (head-to-pelvis in Loeys-Dietz) |
| Marfan, other heritable TAD | yearly | every 3 years |
| bicuspid aortopathy | every 1–3 years | every 3–5 years |
| degenerative | every 1–3 years | every 3–5 years |
| after surgery | — | 12-monthly for 2 years, then every 2 years if stable |
- First repeat at 6–12 months for growth rate (2a); Marfan/Loeys-Dietz TTE at 6 months
- More frequent imaging if within 5 mm of the surgical threshold or growing >2.5–3 mm/y
- MRI preferred when young — <55 y (CCS 2023), <50 y (CCS 2014) — cumulative radiation; same modality and lab each time; TTE alone only if dilation is confined to a well-seen root/proximal ascending
- BAV with root/ascending ≥4.0 cm → lifelong surveillance, including after valve surgery (I)
- After TEVAR: CT at 1 and 12 months, then yearly; after EVAR: CT at 1 month, then duplex at 12 months and yearly if no endoleak (I)
AAA
| Diameter | Ultrasound (ACC/AHA I) |
|---|---|
| 3.0–3.9 cm | every 3 years |
| men 4.0–4.9 · women 4.0–4.4 cm | yearly |
| men ≥5.0 · women ≥4.5 cm | every 6 months |
- CT if ultrasound inadequate (or MRI); CT for repair planning
AAA screening
- CTFPHC 2017: one-time ultrasound for men 65–80 (weak); not men >80 (weak); not women (strong, very low quality). NNS ~311 over 13–15 years to prevent one AAA death; no separate smoker recommendation
- ACC/AHA additionally screens first-degree relatives of AAA patients ≥65 (men and women) (I) and women ≥65 who have ever smoked (2a); no repeat screen after a negative one beyond 75
repair thresholds (asymptomatic, cm)
| Aortopathy | ACC/AHA 2022 | CCS 2014 |
|---|---|---|
| any symptomatic aneurysm | repair regardless of size (I) | repair regardless of size |
| sporadic root/ascending | 5.5 (I); 5.0 at expert aortic centre (2a) | 5.5 |
| rapid growth (sporadic) | ≥0.5 in 1 y or ≥0.3/y for 2 y (I) | >0.5/y |
| concomitant cardiac surgery | TAV repair/replacement: 4.5 at expert centre, 5.0 elsewhere (2a); other cardiac surgery 5.0 (2b) | 4.5 |
| bicuspid valve | 5.5 (I); 5.0–5.4 + risk factor (family history of dissection, growth ≥0.3/y, coarctation, root phenotype) (2a); 5.0–5.4 low surgical risk (2b); ≥4.5 at AVR (2a) | 5.0–5.5 |
| Marfan (root) | 5.0 (I); 4.5 + risk factor (family dissection, growth ≥0.3/y, diffuse root + ascending dilation, marked vertebral tortuosity) (2a) | 5.0; 4.1–4.5 if planning pregnancy |
| familial, no gene identified | guided by family members’ diameters at dissection (I); otherwise 5.0 (I); 4.5 with high-risk features (2a) | 4.5–5.0 |
| Loeys-Dietz | by gene: TGFBR1/2 4.5 (I), 4.0 with high-risk features; SMAD3, TGFB2 4.5 (2a/2b) | 4.0–5.0 (root surgery at 4.2) |
| Turner (≥15 y) | ASI ≥2.5 cm/m² + risk factors (2a) | ASI >2.5 cm/m² |
| vascular Ehlers-Danlos | no threshold — rupture without dilation; aortic team decision | avoid surgery unless imminently life-threatening |
| arch (low operative risk) | 5.5 (2a) | 6.0 degenerative |
| descending | 5.5 (I); earlier with growth 0.5/y, symptoms, HTAD, saccular, female, infection (2b) | 6.5 degenerative; 5.5–6.0 genetic |
| thoracoabdominal (degenerative) | 6.0 (I); 5.5 at expert centre (2a) | — |
| AAA | men 5.5 · women 5.0 (I); growth ≥0.5 in 6 mo or saccular (2b) | — |
choice of procedure
- Descending TAA with suitable anatomy → TEVAR over open (I), except Marfan, Loeys-Dietz or vEDS → open repair
- Elective AAA, low–moderate risk → shared decision open vs EVAR (I); high surgical risk → EVAR (2a)
- Ruptured AAA: stable → CT to assess EVAR suitability (I); EVAR over open when anatomy suits (I); permissive hypotension (SBP ~60–90 mmHg with preserved mentation)
- Where to refer (CCS 2023): most ascending repairs at the local cardiac centre; valve-sparing root, Ross, arch, descending, thoracoabdominal and chronic dissection → tertiary aortic team; follow all aortic disease long term in an aortic clinic
medical management
- BP: treat if ≥130/80 (ACC/AHA I); CCS 2023 target <130/80 → hypertension
- Beta-blocker first, ARB as adjunct (2a each; CCS 2023).
- Marfan: beta-blocker or ARB at maximally tolerated doses regardless of BP (ACC/AHA I; CCS 2014 strong); both together reasonable (2a). Loeys-Dietz: beta-blocker and/or ARB (2a)
- Long-term CCB best avoided in Marfan and other heritable aortopathies unless needed for BP
- Smoking cessation (I) — current smoking doubles AAA rupture risk
- Statin: atherosclerotic AAA (I) or TAA (2a); otherwise may consider (2b)
- Low-dose ASA for atherosclerotic TAA with aortic atheroma or PAU (2a)
- Avoid fluoroquinolones (associated with aneurysm and dissection; CCS 2023 caution)
- Exercise: avoid strenuous resistance/isometric exercise and heavy lifting with strain (CCS 2014); regular moderate aerobic activity encouraged; supervised cardiac rehab is safe
driving (CCS 2014)
| Private | Commercial | |
|---|---|---|
| no driving if ascending > | 6.0 cm | 5.5 cm |
| no driving if descending > | 6.5 cm | 6.0 cm |
| after open repair | 6 weeks | 3 months |
- Sooner after endovascular repair → fitness to drive (cardiac)
pregnancy
- Preconception counselling for all women with aortopathy; beta-blocker through pregnancy and postpartum in heritable TAD; TTE each trimester and postpartum (CCS 2023)
- Caesarean for high aortic risk (CCS 2023): vEDS, Loeys-Dietz, Marfan >45 mm, BAV >50 mm; ACC/AHA: root/ascending ≥4.5 cm (2a) or chronic dissection (I) → heart disease in pregnancy
Prepared 2026-10-19. Not yet verified — check every number against the sources.